Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daren Fearon

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Scientific Reports|June 25, 2021
Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19Martin A Redhead, C David Owen, Lennart Brewitz, et al.
Biorxiv : the Preprint Server for Biology|May 15, 2024
Crystallographic fragment screening and deep mutational scanning of Zika virus NS2B-NS3 protease enable development of resistance-resilient inhibitorsXiaomin Ni, R Blake Richardson, Andre Schutzer Godoy, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2024
Discovery of potent SARS-CoV-2 nsp3 macrodomain inhibitors uncovers lack of translation to cellular antiviral responseAlpha A Lee, Isabelle Amick, Jasmin C Aschenbrenner, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitorEd J Griffen, Daren Fearon, Briana L McGovern, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Discovery of orally bioavailable Zika and West Nile Virus antiviral compounds targeting the NS2B-NS3 proteaseNathaniel T Kenton, Haim Barr, Artem Cherepakha, et al.
Nature Communications|October 8, 2020
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main proteaseAlice Douangamath, Daren Fearon, Paul Gehrtz, et al.
Nature Communications|October 8, 2025
Combined crystallographic fragment screening and deep mutational scanning enable discovery of Zika virus NS2B-NS3 protease inhibitorsXiaomin Ni, R Blake Richardson, Andre Schutzer Godoy, et al.
Biorxiv : the Preprint Server for Biology|December 3, 2020
Fragment Binding to the Nsp3 Macrodomain of SARS-CoV-2 Identified Through Crystallographic Screening and Computational DockingMarion Schuller, Galen J Correy, Stefan Gahbauer, et al.
Science Advances|April 15, 2021
Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational dockingMarion Schuller, Galen J Correy, Stefan Gahbauer, et al.
Journal of Chemical Information and Modeling|February 26, 2026
A Computational Community Blind Challenge on Pan-Coronavirus Drug Discovery DataHugo MacDermott-Opeskin, Jenke Scheen, Cas Wognum, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Scientific Reports|June 25, 2021
Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19Martin A Redhead, C David Owen, Lennart Brewitz, et al.
Biorxiv : the Preprint Server for Biology|May 15, 2024
Crystallographic fragment screening and deep mutational scanning of Zika virus NS2B-NS3 protease enable development of resistance-resilient inhibitorsXiaomin Ni, R Blake Richardson, Andre Schutzer Godoy, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2024
Discovery of potent SARS-CoV-2 nsp3 macrodomain inhibitors uncovers lack of translation to cellular antiviral responseAlpha A Lee, Isabelle Amick, Jasmin C Aschenbrenner, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitorEd J Griffen, Daren Fearon, Briana L McGovern, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Discovery of orally bioavailable Zika and West Nile Virus antiviral compounds targeting the NS2B-NS3 proteaseNathaniel T Kenton, Haim Barr, Artem Cherepakha, et al.
Nature Communications|October 8, 2020
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main proteaseAlice Douangamath, Daren Fearon, Paul Gehrtz, et al.
Nature Communications|October 8, 2025
Combined crystallographic fragment screening and deep mutational scanning enable discovery of Zika virus NS2B-NS3 protease inhibitorsXiaomin Ni, R Blake Richardson, Andre Schutzer Godoy, et al.
Biorxiv : the Preprint Server for Biology|December 3, 2020
Fragment Binding to the Nsp3 Macrodomain of SARS-CoV-2 Identified Through Crystallographic Screening and Computational DockingMarion Schuller, Galen J Correy, Stefan Gahbauer, et al.
Science Advances|April 15, 2021
Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational dockingMarion Schuller, Galen J Correy, Stefan Gahbauer, et al.
Journal of Chemical Information and Modeling|February 26, 2026
A Computational Community Blind Challenge on Pan-Coronavirus Drug Discovery DataHugo MacDermott-Opeskin, Jenke Scheen, Cas Wognum, et al.
Pageof 5